"超级康复":我们可以实现冠状动脉疾病回归吗? 一个可行性研究协议
John Graby1,2, Ali Khavandi1, Fiona Gillison2
1Cardiology, Royal United Hospitals Bath NHS Foundation Trust, Bath, UK.
BMJ open
|December 12, 2023
概括
这项研究测试了超级康复 (SR) 生活方式干预对冠状动脉疾病 (CAD) 患者在初级预防中的可行性. SR可能会改善症状和结果,可能使CAD回归.
科学领域:
- 心脏病学 心脏病学
- 预防医学 预防医学
- 临床试验 临床试验
背景情况:
- 冠状动脉疾病 (CAD) 患者面临着持续的重大不良心血管事件 (MACE) 风险,尽管目前的治疗方法,特别是那些有代谢综合征 (MetS).
- 心脏康复是重血管化后的标准,但缺乏用于CAD初级预防的证据.
- 强化生活方式干预可能提供一种新的方法来改善CAD的结果,并可能逆转疾病的进展.
研究的目的:
- 评估一项多中心随机对照试验 (RCT) 的可行性,用于在CAD患者的初级预防中进行密集的生活方式干预 (超级康复,SR).
- 评估SR的潜力,以改善症状,临床结果,并使CAD回归.
主要方法:
- 一个多中心随机控制的可行性研究,将SR与50名CAD患者 (年龄18-75) 在两个中心的常规护理进行比较.
- 通过招聘,保留和坚持率来评估可行性. 定性访谈探讨了参与者和从业者的经验.
- 序列CT冠状动脉扫描将评估CAD的变化,为未来的RCT设计提供信息.
主要成果:
- 这个部分不在所提供的摘要中.
- 这个部分不在所提供的摘要中.
- 这个部分不在所提供的摘要中.
结论:
- 为超级康复干预提供多中心RCT的可行性需要进一步调查.
- 结果将指导未来的大规模RCT的设计和功率计算,评估SR在CAD初级预防中的有效性.
更多相关视频
10:28Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
5.0K
13:07Optical Coherence Tomography Based Biomechanical Fluid-Structure Interaction Analysis of Coronary Atherosclerosis Progression
Published on: January 15, 2022
3.9K
相关概念视频
01:30Coronary Artery Disease I: Introduction
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
01:26Coronary Artery Disease IV: Preventive Measures
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
01:27Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
01:30Acute Coronary Syndrome III: Diagnostic Studies
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
01:28Acute Coronary Syndrome IV: Interprofessional Care
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...